TRVI Trevi Therapeutics, Inc. Common Stock Loading...

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
05:59
Jul 27
seedy19tron Biotech trader, L/S
Author highlights Affinity's golden run in biotech and their top 5 FBRX holding post-APGE acquisition, celebrating broad sector gains without explicit forward calls on most names.
TRVI
LOW
18:41
Jul 20
seedy19tron Biotech trader, L/S
Short as GSK failure does not de-risk TRVI's Phase 3; BP disinterest undermines scarcity thesis.
TRVI
MED
12:01
Jul 17
seedy19tron Biotech trader, L/S
Buy TRVI as camlipixant discontinuation removes a competitive drug from the landscape, improving TRVI's relative positioning; speaker views the stock as more attractive despite potential "priced in" caveat.
TRVI 1ST
MED
22:58
May 17
seedy19tron Biotech trader, L/S
"Checkpoint Capital opened new positions in CRNX, SEPN, TRVI in Q1 2026. Fund disclosure, no speaker thesis."
TRVI
HIGH

About TRVI Analyst Coverage

Buzzberg tracks TRVI (Trevi Therapeutics, Inc. Common Stock) across 1 sources. 1 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (25%). 4 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: seedy19tron.